Business · 04/04/2005

FDA Releases Draft Guidance on Clinical Trial Endpoints for Cancer Drug Approval

The Food and Drug Administration (FDA) has made available a draft guidance document outlining recommended endpoints for cancer clinical trials submitted to support effectiveness claims in new drug applications and biologics license applications, with the aim of accelerating the development and improvement of cancer treatment protocols.